|Application ||WB, IHC, IF, FC, IP|
|Other Names||Napsin-A, 3423-, Aspartyl protease 4, ASP4, Asp 4, Napsin-1, TA01/TA02, NAPSA, NAP1, NAPA|
|Target/Specificity||A synthetic peptide RFDPKASSSFQANGTKFAIQYGT of human Napsin-A|
|Application Note||Flow Cytometry : 0.5-1ug/million cells|
Immunofluorescence : 1-2ug/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 1-2ug/500ug protein lysate
Immunohistology (formalin-fixed) : 1-2ug/ml for 30 minutes at RT
(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes).
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Napsin A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May be involved in processing of pneumocyte surfactant precursors.|
|Tissue Location||Expressed predominantly in adult lung (type II pneumocytes) and kidney and in fetal lung. Low levels in adult spleen and very low levels in peripheral blood leukocytes|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Napsin is a pepsin-like aspartic proteinase connected with maturation of surfactant protein B. There are two closely related napsins, napsin A and napsin B. Napsin A is expressed as a single chain protein. Immunohistochemical studies revealed high expression levels of napsin A in human lung and kidney but low expression in spleen. Napsin A is expressed in type II pneumocytes and in adenocarcinomas of lung. The high specificity expression of napsin A in adenocarcinomas of lung is useful to distinguish primary lung adenocarcinomas from adenocarcinomas of other organs.
1. Bishop, JA et. al. Hum Pathol 41: 20-25
2. Ordonez, NG 2012 Adv Anat Pathol 19: 66-73
3. Ye, J et. al. Appl Immunhistochem Mol Morphol 19: 313-317
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.